The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,239,683 in first-year total cost, median $216,841.
Most frequent study sections
- Special Emphasis Panel[ZAI1 SM-M (J2)]10
- Special Emphasis Panel[ZAI1 SM-M (J1)]6
Most frequent institutions
- UNIV OF NORTH CAROLINA CHAPEL HILL2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- HARVARD MEDICAL SCHOOL1
- JOHNS HOPKINS UNIVERSITY1
- LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Host-Targeted Homoserine Lactone Inhibitor as Adjunctive Antipseudomonal Therapy1R21AI111634-01 | HAGGIE, PETER MICHAEL | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $236,500 | ZAI1 |
| 2014 | Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB1R21AI111739-01 | LAMICHHANE, GYANU | JOHNS HOPKINS UNIVERSITY, MD | $236,056 | ZAI1 |
| 2014 | Targeting cell separation systems of gram-negative bacteria.1R21AI111713-01 | BERNHARDT, THOMAS G | HARVARD MEDICAL SCHOOL, MA | $230,932 | ZAI1 |
| 2014 | PFOR inhibitor amixicile for treatment of drug resistant parasites and bacteria1R21AI111604-01 | HOFFMAN, PAUL STOKES | UNIVERSITY OF VIRGINIA, VA | $229,100 | ZAI1 |
| 2014 | Targeting a New Essential Virulence Mechanism in Drug-Resistant Mycobacteria1R21AI111696-01 | STALLINGS, CHRISTINA LEIGH | WASHINGTON UNIVERSITY, MO | $222,225 | ZAI1 |
| 2014 | Antibiotic targeting of protein interfaces in bacterial genome maintenance comple1R21AI111676-01 | ANDES, DAVID RKECK, JAMES L | UNIVERSITY OF WISCONSIN-MADISON, WI | $221,710 | ZAI1 |
| 2014 | Generation of recombinant thiopeptides to target antimicrobial-resistant bacteria1R21AI111662-01 | WELLS, JAMES A | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $220,814 | ZAI1 |
| 2014 | Discovery and validation of drug targets in vulnerable pathways of Mtb1R21AI111647-01 | ALLAND, DAVID | RBHS-NEW JERSEY MEDICAL SCHOOL, NJ | $218,623 | ZAI1 |
| 2014 | Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics1R21AI111753-01 | GELLER, BRUCE LGREENBERG, DAVID ELIHU | UT SOUTHWESTERN MEDICAL CENTER, TX | $215,059 | ZAI1 |
| 2014 | Antibiotic Potentiation by Targeting of a Signal Transduction System1R21AI111760-01 | BOYLE-VAVRA, SUSANDAUM, ROBERT S. | UNIVERSITY OF CHICAGO, IL | $212,782 | ZAI1 |
| 2014 | Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae1R21AI111728-01 | RAM, SANJAYSHAUGHNESSY, JUTAMAS | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $208,854 | ZAI1 |
| 2014 | Validation and development of trans-translation as a drug target for MRSA1R21AI111692-01 | KEILER, KENNETH C | PENNSYLVANIA STATE UNIVERSITY, THE, PA | $208,596 | ZAI1 |
| 2014 | Exploiting Host Polyamines for the Treatment of Skin and Wound Infections1R21AI111707-01 | RICHARDSON, ANTHONY R. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $197,600 | ZAI1 |
| 2014 | Mitigating Resistance & Virulence in MRSA1R21AI111661-01 | YEAMAN, MICHAEL R | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $190,268 | ZAI1 |
| 2014 | Targeting SecA1 of Mycobacterium tuberculosis for Novel Drug Development1R21AI111667-01 | BRAUNSTEIN, MIRIAM S.FRYE, STEPHEN VERNON | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $186,787 | ZAI1 |
| 2014 | Development of adjunctive therapies directed at S. aureus amidases1R21AI111638-01 | BOLES, BLAISE R | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $3,777 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.